TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6410104
Drug: Fast neutron
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast neutron therapy (average energy, 6 MeV)
Study: 6410104
Drug: Linac x-ray
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linac x-ray therapy (10 MV)
Study: 6410104
Drug: Linac x-ray
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linac x-ray therapy
Study: 6410104
Drug: Fast neutron
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast neutron therapy and Linac x-ray therapy
Study: 26204126
Drug: COC pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: COC pills
Study: 22453191
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg intranasal midazolam
Study: 22453191
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg intranasal midazolam
Study: 22453191
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intravenous midazolam
Study: 19236375
Drug: Intranasal desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal desmopressin (IN‐DDAVP)
Study: 17577015
Drug: Boost dose
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boost dose of 16 Gy (2,661 patients)
Study: 17577015
Drug: No boost
Approvals — FDA: no, EMA: no, PMDA: no
Description: No boost dose (2,657 patients)
Study: 31394283
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus albumin (study group)
Study: 21952668
Drug: MDMA 50
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 50 mg
Study: 16830130
Drug: MDMA 100
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 100 mg
Study: 10671903
Drug: MDMA 150
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 150 mg
Study: 10671903
Drug: MDMA (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (all doses tested)
Study: 9348549
Drug: m-chlorophenylpiperazine (mCPP)
Normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-chlorophenylpiperazine (mCPP) 0.1 mg/kg during TRP depletion
Study: 9348549
Drug: m-chlorophenylpiperazine (mCPP)
Normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-chlorophenylpiperazine (mCPP) 0.1 mg/kg during sham depletion
Study: 26024940
Drug: Combined Oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Oral Contraceptives (COC)
Study: 29352713
Drug: Sipuleucel-T immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sipuleucel-T immunotherapy
Study: 22648716
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution with alcohol (21 g alcohol, 25 g carbohydrates)
Study: 22648716
Drug: Beer (4.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beer (4.5% alcohol by volume, 25 g carbohydrates)
Study: 22648716
Drug: Nonalcoholic beer
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonalcoholic beer (25 g carbohydrates)
Study: 22648716
Drug: Reference glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference glucose solution (25 g carbohydrates)
Study: 15972322
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin C supplementation (250 mg three times per week for 2 months)
Study: 2538962
Drug: Simultaneous radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous radiation and chemotherapy (group 1)
Study: 2538962
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy followed by radiation (group 2)
Study: 2538962
Drug: Chemotherapy responders
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy responders in group 2
Study: 25008011
Drug: Salacia reticulata
Normalized name: Salacia reticulata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salacia reticulata and Vitamin D₃ (200 mg of Salacia reticulata and 1.6 µg Vitamin D₃ 3 times/day with meals)
Study: 16873329
Drug: Custom-designed dental
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Custom-designed dental scaling instruments with a large diameter (10 mm) and light weight (15 g)
Study: 16873329
Drug: Custom-designed dental
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Custom-designed dental scaling instruments lighter than 15 g
Study: 12615252
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium 15 mmol twice daily (Magnosolv‐Granulat, total magnesium 365 mg provided as magnesium citrate)
Study: 11234440
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of steam and aerosol using municipal drinking water (group C)
Study: 8868018
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone regimen
Study: 1519685
Drug: Topical nonsteroidal
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nonsteroidal anti-inflammatory gel
Study: 30194849
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) patch
Study: 30194849
Drug: No GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: No GTN patch
Study: 30194849
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment continued
Study: 30194849
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment stopped
Study: 21080972
Drug: QUIT-PRIMO intervention
Normalized name: Primor
Approvals — FDA: no, EMA: no, PMDA: no
Description: QUIT-PRIMO intervention (e-referral with paper information-prescription referral)
Study: 21080972
Drug: Augmented patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented patient smoking cessation website (with access to a tobacco treatment specialist online, motivational emails, and an online support group)
Study: 12834860
Drug: Brivudin 1
Normalized name: Brivudine
DrugBank: Brivudine (DB03312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivudin 1 x 125 mg for 7 days
Study: 12834860
Drug: Acyclovir 5
Normalized name: acyclovir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 5 x 800 mg for 7 days
Study: 10230711
Drug: Tyrosine-rich drink
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tyrosine-rich drink (2 g tyrosine, 5 daily doses)
Study: 1871541
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg twice daily)
Study: 3914014
Drug: Merck‐Sharp and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merck‐Sharp and Dohme pneumococcal vaccine (14 serotypes)
Study: 27433096
Drug: Topical hemocoagulase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hemocoagulase spray
Study: 27433096
Drug: Traditional 8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional 8% norepinephrine spray
Study: 23886594
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (HCTZ and ATEN)
Study: 21975176
Drug: Allergy vaccination
Normalized name: Callergy Clear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergy vaccination (specific immunotherapy)
Study: 15725286
Drug: 0.04% MDBGN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04% MDBGN applied once daily
Study: 15725286
Drug: 0.01% MDBGN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% MDBGN applied 4 times daily
Study: 10383522
Drug: OAC (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC (omeprazole 20 mg b.d., amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Study: 8710739
Drug: Rac-talinolol 30
Normalized name: talinolol
DrugBank: Talinolol (DB11770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rac-talinolol 30 mg i.v. and 100 mg p.o. in cholecystectomized patients
Study: 8710739
Drug: Rac-talinolol 25
Normalized name: talinolol
DrugBank: Talinolol (DB11770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rac-talinolol 25 mg, 50 mg, 100 mg, and 400 mg p.o. in healthy volunteers
Study: 1987387
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg) + Dipyridamole (150 mg)
Study: 6352081
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (500,000 IU over 15 min)
Study: 6352081
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (1 million IU over 45 min)
Study: 28856435
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of triamcinolone
Study: 18654082
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg/day) - fully informed group
Study: 18654082
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg/day) - partially informed group
Study: 18654082
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg/day) - not informed group
Study: 15387395
Drug: Triplicate Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplicate Prescription Program (TPP) in New York
Study: 3127243
Drug: Terguride 1
Normalized name: terguride
DrugBank: Terguride (DB13399)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Terguride 1 mg
Study: 2616602
Drug: Bromocriptine 2.5
Normalized name: bromocriptine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 2.5 mg
Study: 3127243
Drug: Terguride lower
Normalized name: terguride
DrugBank: Terguride (DB13399)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Terguride lower doses
Study: 28231782
Drug: D3 daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3 daily
Study: 28231782
Drug: D3 2-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3 2-weekly
Study: 28231782
Drug: D2 daily
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 daily
Study: 28231782
Drug: D2 2-weekly
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 2-weekly
Study: 28231782
Drug: D2 4-weekly
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 4-weekly
Study: 25979180
Drug: School-based sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based sleep education programme (four classroom lessons delivered weekly)
Study: 20519876
Drug: Inhaled iloprost
Normalized name: iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iloprost
Study: 20956120
Drug: Inhaled iloprost
Normalized name: iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iloprost in combination with oral bosentan
Study: 16846448
Drug: Ding Chuan
Normalized name: Ding xiang
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ding Chuan Tang (DCT) 6.0 g daily for 12 weeks
Study: 12968988
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg orally once daily for 5 days
Study: 8375733
Drug: Natural interferon-beta
Normalized name: interferon beta natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural interferon-beta (IFN-beta) at two different dose levels (2 x 10(6) IU or 6 x 10(6) IU im 3 times/week for 1 week)
Study: 26922655
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication discontinuation
Study: 26922655
Drug: Successful discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful discontinuation (defined as no relapse within the observation period)
Study: 26922655
Drug: Successful discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful discontinuation (defined as no relapse and symptomatic remission at 12-month follow-up)
Study: 26922655
Drug: Discontinuation predictors
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation predictors
Study: 26922655
Drug: Successful discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful discontinuation predictors (definition a)
Study: 26922655
Drug: Successful discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful discontinuation predictors (definition b)
Study: 22813676
Drug: WPS (Workplace
Approvals — FDA: no, EMA: no, PMDA: no
Description: WPS (Workplace Solutions) intervention group
Study: 18942901
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg tid; n = 12)
Study: 16158479
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (n=74)
Study: 12934778
Drug: Transdermal oxybutynin
Normalized name: oxybutynin Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oxybutynin (Oxytrol, 3.9 mg/d)
Study: 12934778
Drug: Extended-release oral
Normalized name: Carbinoxamine Maleate Extended-Release Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release oral oxybutynin (Ditropan XL, 10 mg)
Study: 10393376
Drug: Trimethoprim-sulfamethoxazole (trimethoprim,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (trimethoprim, 320 mg/day; sulfamethoxazole, 1,600 mg/day)
Study: 10393376
Drug: Other antibiotics
Normalized name: Other antibiotics for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antibiotics (control group)
Study: 8894571
Drug: Zidovudine (AZT)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (AZT) 1 g/day
Study: 3318145
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg PG E2 endocervically
Study: 3318145
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg PG E2 intravaginally
Study: 26455718
Drug: Artificial endometrial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial endometrial cycle treatment (AEC)
Study: 17977859
Drug: Ropivacaine 0.165%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.165% with sufentanil 1 microg ml(‐1)
Study: 17977859
Drug: Levobupivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.125% with sufentanil 1 microg ml(‐1)
Study: 16365120
Drug: Clamping the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clamping the drains after intra‐articular injection of saline with 1:500 000 adrenaline
Study: 7674690
Drug: Judicious prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Judicious prescription of therapies in stepwise fashion
Study: 2469338
Drug: Hypertonic saline‐dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline‐dextran solution
Study: 23328847
Drug: Radio-frequency nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radio-frequency nerve ablation (RFNA) after crossover from sham treatment
Study: 29525602
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg bevacizumab
Study: 24923077
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg bevacizumab
Study: 14969649
Drug: Glyburide/metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide/metformin plus rosiglitazone (4 mg once daily)
Study: 14969649
Drug: Glyburide/metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide/metformin plus rosiglitazone
Study: 14969649
Drug: Glyburide/metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide/metformin plus placebo
Study: 9403284
Drug: Erythromycin 1
Normalized name: erythromycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 1 g b.i.d. for 5 days
Study: 9403284
Drug: Dirithromycin 500
Normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dirithromycin 500 mg qd for 5 days
Study: 8144986
Drug: Radiotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy alone (4 Gy per fraction, three fractions per week to a total dose of 24 Gy)
Study: 31084381
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (400 mg daily for 12 weeks)
Study: 24180479
Drug: i.v. mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. mitoxantrone (MTX), oral vinorelbine, or oral etoposide, together with oral prednisone
Study: 23242572
Drug: NR-INF-02 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: NR-INF-02 (500 mg twice daily)
Study: 23242572
Drug: Placebo (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (400 mg twice daily)
Study: 23242572
Drug: Glucosamine sulphate
Normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulphate (GS) (750 mg twice daily)
Study: 23242572
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NR-INF-02 and GS
Study: 18083691
Drug: ILF (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: ILF (irinotecan 150 mg/m², leucovorin 20 mg/m², 5-FU 1000 mg/m² on days 1 and 2)
Study: 18083691
Drug: PILF (ILF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PILF (ILF plus cisplatin 30 mg/m² on day 2)
Study: 12660333
Drug: Benazepril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (20 mg once daily)
Study: 15533733
Drug: Valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80 mg once daily)
Study: 12660333
Drug: Dual blockade
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual blockade (20 mg benazepril + 80 mg valsartan)
Study: 10971305
Drug: Stevioside (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stevioside (250 mg) thrice daily
Study: 8832991
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg equivalent)
Study: 1449107
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) at 540 mg/m2 with folinic acid (FA) 500 mg/m2 and rhGM-CSF
Study: 1449107
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) at 450 mg/m2 with folinic acid (FA) 500 mg/m2 and rhGM-CSF
Study: 6150276
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg or 150 mg kanamycin plus gentamicin eye ointment (for 3 days)
Study: 6150276
Drug: Single-dose kanamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose kanamycin with saline eye washes (for 3 days)
Study: 6150276
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg kanamycin plus chloramphenicol eye drops
Study: 28443675
Drug: Palmar proximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmar proximal injection approach
Study: 28443675
Drug: Palmar distal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmar distal injection approach
Study: 28443675
Drug: Webspace injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Webspace injection approach
Study: 26676838
Drug: O2-O3 intradiscal
Normalized name: O3-Methylmorphine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: O2-O3 intradiscal injection
Study: 19012050
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated estrogen (CE) + 2.5 mg medroxyprogesterone acetate (MPA)/day
Study: 19012050
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg tibolone/day
Study: 9023459
Drug: Inulin (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (7 g)
Study: 9023459
Drug: Oligofructose (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose (17 g)
Study: 9023459
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (7 g of sucrose)
Study: 8420063
Drug: OKT3 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3 plus azathioprine and steroids for 14 days with delayed addition of cyclosporine on day 11
Study: 8420063
Drug: Conventional immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunosuppression (steroids, azathioprine, and cyclosporine)
Study: 3106632
Drug: 125 mg/day
Normalized name: infigratinib phosphate 125 mg/day (100 mg x 1 and 25 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg/day D‐penicillamine
Study: 3106632
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg D‐penicillamine
Study: 31237134
Drug: OM3-FAs 4,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3-FAs 4,000 mg plus atorvastatin 20 mg
Study: 31237134
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg plus placebo
Study: 28039060
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral calcium supplementation
Study: 25365032
Drug: Caffeinated carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated carbohydrate gel (CC) - 21.6 g carbohydrate, 100 mg caffeine